MEIER ULRICH,BIERI NICOLE,BECKER DIETER,TAILLEMITE JULIEN,FILLIOT MARIE PIERRE,MEISTER TANJA
申请号：
IN1858/KOLNP/2013
公开号：
IN2013KN01858A
申请日:
2013.06.10
申请国别(地区):
IN
年份:
2013
代理人:
摘要：
The present invention relates to a novel crystalline anhydrous form of [(5 chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6- fluoro-7-(methylamino)-2,4-dioxo-1,2- dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt,and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals,particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form,its preparation and use thereof.
